|
Scale
|
ASTERIA I
|
ASTERIA II
|
GLACIAL
|
|---|
|
Placebo
|
Omalizumab 75 mg
|
Omalizumab 150 mg
|
Omalizumab 300 mg
|
Placebo
|
Omalizumab 75 mg
|
Omalizumab 150 mg
|
Omalizumab 300 mg
|
Placebo
|
Omalizumab 300 mg
|
|---|
|
MOS-Sleep Scale, SPI-II, n
|
63
|
67
|
63
|
72
|
70
|
70
|
70
|
73
|
62
|
217
|
|
Mean (SD)
|
−1.7 (18.0)
|
−14.4 (18.6)
|
−11.8 (20.6)
|
−18.1 (21.6)*
|
−10.8 (16.7)
|
−15.5 (20.0)
|
−16.4 (15.4)*
|
−16.8 (19.4)*
|
−13.4 (15.8)
|
−19.0 (20.5)***
|
|
UPDD Weekly Sleep Interference Score, n
|
62
|
64
|
63
|
73
|
69
|
68
|
73
|
74
|
67
|
214
|
|
Mean (SD)
|
−5.0 (5.3)
|
−7.0 (5.6)
|
−7.1 (6.0)*
|
−9.6 (5.3)**
|
−6.2 (5.7)
|
−6.8 (6.7)
|
−7.8 (6.4)
|
−9.2 (5.8)**
|
−5.0 (6.5)
|
−9.2 (5.3)**
|
|
CU-Q2oL Sleep Problems domain, n
|
49
|
50
|
48
|
57
|
62
|
59
|
61
|
65
|
60
|
210
|
|
Mean (SD)
|
−18.8 (23.5)
|
−20.5 (21.6)
|
−22.1 (25.4)
|
−30.2 (23.8)
|
−18.0 (24.2)
|
−22.6 (23.4)
|
−25.2 (26.4)
|
−33.3 (24.9)**
|
−18.3 (22.2)
|
−29.4 (23.8)**
|
-
CU-Q
2
oL Chronic Urticaria Quality of Life Questionnaire, MOS-Sleep Scale Medical Outcomes Study Sleep Scale, SPI-II Sleep Problem Index II, UPDD Urticaria Patient Daily Diary
- Adjusted * p < 0.05; ** p < 0.001; *** p < 0.01, versus placebo
